Clinical Trial Update: Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the effect of rifaximin on the gut microbiota and metabolome in small intestinal bacterial overgrowth (SIBO) using CapScan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Intestinal Bacterial Overgrowth

Drugs mentioned

• Rifaximin (Xifaxan) (rifaximin)

Snippet

Sponsor: Envivo Bio Inc | Conditions: Small Intestinal Bacterial Overgrowth | Phase 1 | Status: RECRUITING